Journal Article

Microbiological profile of patients treated for postoperative peritonitis: temporal trends 1999–2019

Kantor, Elie, Zappella, Nathalie, Montravers, Philippe, Grall, Nathalie, Augustin, Pascal, Boussion, Kevin

2023

Overview

Background Temporal changes in the microbiological resistance profile have been reported in several life-threatening infections. However, no data have ever assessed this issue in postoperative peritonitis (POP). Our purpose was to assess the rate of multidrug-resistant organisms (MDROs) in POP over a two-decade period and to analyse their influence on the adequacy of empirical antibiotic therapy (EAT). Methods This retrospective monocentric analysis (1999–2019) addressed the changes over time in microbiologic data, including the emergence of MDROs and the adequacy of EAT for all intensive care unit adult patients treated for POP. The in vitro activities of 10 antibiotics were assessed to determine the most adequate EAT in the largest number of cases among 17 antibiotic regimens in patients with/without MDRO isolates. Our primary endpoint was to determine the frequency of MDRO and their temporal changes. Our second endpoint assessed the impact of MDROs on the adequacy of EAT per patient and their temporal changes based on susceptibility testing. In this analysis, the subgroup of patients with MDRO was compared with the subgroup of patients free of MDRO. Results A total of 1,318 microorganisms were cultured from 422 patients, including 188 (45%) patients harbouring MDROs. The growing proportions of MDR Enterobacterales were observed over time ( p  = 0.016), including ESBL-producing strains ( p  = 0.0013), mainly related to Klebsiella spp ( p  < 0.001). Adequacy of EAT was achieved in 305 (73%) patients. Decreased adequacy rates were observed when MDROs were cultured [ p  = 0.0001 vs. MDRO-free patients]. Over the study period, decreased adequacy rates were reported for patients receiving piperacillin/tazobactam in monotherapy or combined with vancomycin and imipenem/cilastatin combined with vancomycin ( p  < 0.01 in the three cases). In patients with MDROs, the combination of imipenem/cilastatin + vancomycin + amikacin or ciprofloxacin reached the highest adequacy rates (95% and 91%, respectively) and remained unchanged over time. Conclusions We observed high proportions of MDRO in patients treated for POP associated with increasing proportions of MDR Enterobacterales over time. High adequacy rates were only achieved in antibiotic combinations involving carbapenems and vancomycin, while piperacillin/tazobactam is no longer a drug of choice for EAT in POP in infections involving MDRO. Graphical Abstract

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adequate empirical therapy / Adult / Analysis / Anti-Bacterial Agents - therapeutic use / Antibiotics / Bacteria / Beta lactamases / Care and treatment / Cilastatin, Imipenem Drug Combination - therapeutic use / Ciprofloxacin / Drug resistance in microorganisms / Drug Resistance, Multiple, Bacterial / Emergency Medicine / Empirical antibiotic therapy / Health aspects / Humans / Infection / Medical research / Medicine / Medicine & Public Health / Medicine, Experimental / Metronidazole / Microbiology / Multidrug resistant organisms / Multidrug-resistant bacteria / Optimal empirical therapy / Patients / Peritonitis / Peritonitis - drug therapy / Piperacillin - therapeutic use / Postoperative peritonitis / Retrospective Studies / Staphylococcus infections / Surgery / Tazobactam - therapeutic use / Traumatic Surgery / Trends / Vancomycin - therapeutic use